Clinical Trial Update: Dose-escalation Study of Combination BMS-936558 (MDX-1106) and Ipilimumab in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma [Phase 1]

View source ↗

Summary

Phase 1 dose-escalation study of combining BMS-936558 (MDX-1106) with ipilimumab in unresectable stage III/IV malignant melanoma completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Melanoma

Drugs mentioned

• BMS-936558 (MDX-1106) (nivolumab)
• ipilimumab (ipilimumab)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Malignant Melanoma | Phase 1 | Status: COMPLETED | Results posted: 2021-03-22